The Liver Left Behind: GLP-1 Receptor Agonists and the Prospect of Metabolic Adjuvant Therapy After HCC Resection
Abstract
Hepatocellular carcinoma (HCC), the most common histological type of primary liver cancer (PLC), remains one of the most consequential malignancies arising in chronic liver disease, in part because its incidence and mortality rates remain closely aligned [...].
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.